Diabetic Cardiomyopathy: An Immunometabolic Perspective

Area of Science:

• Cardiology
• Metabolic Diseases
• Molecular Biology

Background:

• Diabetic cardiomyopathy (DCM) is a distinct cardiac condition in diabetes, characterized by structural and functional changes.
• Early DCM involves metabolic shifts, oxidative stress, and inflammation, preceding overt heart failure.
• The diabetic heart exhibits metabolic inflexibility, favoring fatty acid oxidation over glucose, which is energetically inefficient.

Purpose of the Study:

• To review the critical roles of immunometabolism and microRNAs in the pathogenesis of diabetic cardiomyopathy.
• To elucidate the mechanisms linking altered substrate metabolism, immune cell function, and cardiac dysfunction in diabetes.

Main Methods:

• Review of existing literature on diabetic cardiomyopathy, focusing on metabolic and immune pathways.
• Analysis of the interplay between cellular energy metabolism, inflammatory responses, and cardiac remodeling.
• Examination of the role of microRNAs in regulating these processes.

Main Results:

• Diabetic hearts exhibit impaired calcium handling and reduced SERCA2a activity, affecting excitation-contraction coupling.
• Metabolic inflexibility and inefficient fatty acid oxidation contribute to cardiac dysfunction.
• Dysregulated immune responses and increased fibrosis are key features of DCM progression.
• Downregulation of cardioprotective microRNAs exacerbates cardiac damage in diabetes.

Conclusions:

• Altered immunometabolism and microRNA dysregulation are central to diabetic cardiomyopathy development.
• Targeting metabolic pathways and microRNAs offers potential therapeutic strategies for DCM.
• Understanding these mechanisms is crucial for preventing and treating diabetic heart disease.